This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates
by Zacks Equity Research
So far this earnings season, the going seems to be good for the medical sector. Let us take a glance at a few small drug companies, which are likely to beat on Q1 earnings.
3 Reasons Why Growth Investors Shouldn't Overlook Jazz (JAZZ)
by Zacks Equity Research
Jazz (JAZZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.
Jazz Pharmaceuticals (JAZZ) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 16.14% and 7.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
JAZZ vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
3 Reasons Why Jazz (JAZZ) Is a Great Growth Stock
by Zacks Equity Research
Jazz (JAZZ) could produce exceptional returns because of its solid growth attributes.
Concert Pharma Initiates Early-Stage Schizophrenia Study
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) announces initiation of multiple-ascending dose phase I study to evaluate its pipeline candidate, CTP-692, as an adjunctive treatment for schizophrenia.
Jazz (JAZZ) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) announced positive top-line data from its phase III study on low sodium formulation of Xyrem, JZP-258.
Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision
by Zacks Equity Research
The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.
Is Jazz Pharmaceuticals (JAZZ) a Good Value Investor Pick?
by Zacks Equity Research
Let's see if Jazz Pharmaceuticals (JAZZ) stock is a good choice for value-oriented investors right now from multiple angles.
The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom
The Best And Worst Stocks of the 10-Year Bull Market
by Tirthankar Chakraborty
We highlight some of the best and worst stocks over the bull market's 10 years.
Jazz Pharmaceuticals (JAZZ) Surges: Stock Moves 7.9% Higher
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Jazz Pharma (JAZZ) Q4 Earnings & Sales Beat, Stock Up 8%
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) surpasses earnings and sales estimates in the fourth quarter and issues a solid outlook for 2019. Shares rise 8% in after-hours trading.
Mylan (MYL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when the company reports Q4 results.
Factors to Know Ahead of Herbalife's (HLF) Q4 Earnings
by Zacks Equity Research
Herbalife (HLF) is likely to gain from its direct-selling network, product portfolio and solid volumes. However, unfavorable currency movements and stiff competition may hurt the bottom line.
Why Jazz (JAZZ) Could Beat Earnings Estimates Again
by Zacks Equity Research
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jazz Inks Deal with Codiak to Develop Exosome Therapeutics
by Zacks Equity Research
Jazz (JAZZ) collaborates with Codiak for research, development and commercialization of exosome therapeutics to treat cancer.
Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA
by Zacks Equity Research
Jazz (JAZZ) announces that the FDA has extended the review period of its new drug application for sleep drug, solriamfetol, by three months to Mar 20, 2019.
Jazz (JAZZ) Increases Share Buyback Authorization by $400M
by Zacks Equity Research
Jazz's (JAZZ) board sanctions a raise in its share buyback authorization by $400 million.